Company Overview of Angiochem Inc.
Angiochem Inc., a clinical-stage biotechnology company, engages in discovering and developing peptide drug conjugates for the treatment of neurological diseases. The company focuses on developing small molecules and biologics for the treatment of a range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases, pain, and other diseases. It develops ANG1005, a taxane derivative that leverages low density lipoprotein receptor-related protein 1 (LRP-1) to cross the blood-brain barrier (BBB) and enter cancer cells; peptide antibody conjugates; ANG4043, an anticancer therapy to treat breast cancer metastases in the brain; antibody-drug conjugates that cross th...
201 President-Kennedy Avenue
Montreal, QC H2X 3Y7
Founded in 2003
Key Executives for Angiochem Inc.
Vice President of Development
Compensation as of Fiscal Year 2016.
Angiochem Inc. Key Developments
Angiochem's ANG1005 Shows Clinical Benefits and Prolonged Survival for Breast Cancer Patients with Brain Metastases
Oct 17 16
Angiochem presented data from its Phase II trial for its lead compound, ANG1005. In this report of the multi-center, open label Phase II trial ANG1005-CLN-04, ANG1005 demonstrated clinical benefit, both intracranially and extracranially in pretreated breast cancer patients with recurrent brain metastases. The data on those patients enrolled in ANG1005-CLN-04 who had leptomeningeal carcinomatosis (LC) as well as recurrent breast cancer brain metastasis was updated at the 12th EANO Meeting, Mannheim, Germany.
Angiochem Announces Successful End-Of-Phase 2 Meeting with FDA for ANG1005
Jun 23 16
Angiochem announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for ANG1005. As a result, the company is in final preparation stages to commence its Phase 3 trial to support a New Drug Application (NDA) for ANG1005 in patients with leptomeningeal carcinomatosis (LC) from breast cancer. The trial design for the single pivotal study is a randomized two-arm superiority trial in breast cancer patients with recurrent brain metastases (BCBM patients) and LC. The primary efficacy endpoint of the study is a significant improvement in overall survival with ANG1005 compared to treatment with Physicians' Best Choice. ANG1005 demonstrated clinical benefit, both intracranially and extracranially in pretreated BCBM patients with LC in the company's Phase 2 trial.
Angiochem Announces Executive Appointments
Apr 28 16
Angiochem appointed Mr. John Huss as Executive Chairman and elected a new board of directors. John Huss has more than 25 years of global pharmaceutical experience. He spent 20 years with Merck & Co., Roche and Sanofi on the pharmaceutical side of the business, before moving to biotechnology. He served as CEO, President and Director of Theratechnologies and is currently Founder, President and CEO of H&P Labs Inc. He is also Vice-President, member of the Executive Committee and a Director at BioQuebec. The board also appointed Robert Blain as a board of director. Robert Blain, with more than 20 years in the international entertainment industry, is Co-CEO of Groupe Lune Rouge Inc. As well as taking care of the Family office of Mr. Guy Laliberte, Mr. Blain also acts as an investment manager in Lune Rouge. Since 2007, Mr. Blain has been an administrator and treasurer for One Drop Foundation which aims to fight poverty by supporting access to water worldwide. He also sits as the Treasurer on Sainte-Justine UHC Foundation, one of the most important pediatric centers in North America.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|